Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 12/20 | 0.44 |
| ▸ | CMA1 | P23946 | 11/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923732 | 0.89 | CTSG (0.46) | CTSGCMA1SHMT2MEN1NPC1 | |
| SCHEMBL19923623 | 0.80 | NPC1 (0.48) | CTSGCMA1MEN1NPC1RAB9A | |
| SCHEMBL19923494 | 0.77 | ENPP2 (0.46) | CTSGCMA1MEN1KMT2A | |
| SCHEMBL19923512 | 0.75 | NPC1 (0.47) | CTSGCMA1MEN1NPC1RAB9A | |
| SCHEMBL11082167 | 0.73 | MAPT (0.50) | CTSGCMA1SHMT2MEN1NPC1 | |
| SCHEMBL2191993 | 0.73 | HTT (0.51) | CTSGCMA1MEN1NPC1RAB9A | |
| SCHEMBL19923645 | 0.72 | PLA2G7 (0.33) | KMT2AMAPT | |
| SCHEMBL11089881 | 0.71 | RAB9A (0.50) | CTSGCMA1MEN1NPC1RAB9A | |
| SCHEMBL19923571 | 0.70 | F2 (0.30) | CTSG | |
| SCHEMBL2536250 | 0.70 | NPC1 (0.54) | CTSGCMA1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | CTSG 1654/4885CMA1 4120/4885SHMT2 1516/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | CTSG 1736/4885CMA1 3987/4885SHMT2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.